A qualitative analysis of seven ivermectin formulations in South Africa
Some South African (SA) healthcare practitioners are promoting the prescription and use of products claiming to contain ivermectin for the treatment and/or prevention of COVID-19 in SA. This study qualitatively analysed seven samples of ivermectin formulations (5 tablet and 2 capsule formulations) being sold in SA for human use. The samples were analysed using a high-performance liquid chromatography instrument connected to a Sciex X500R quadrupole time-of-flight high-resolution mass spectrometer. The study found that all the samples had both the major homologues of ivermectin (B1a and B1b) and also that 4 out of the 5 tablet formulations tested had at least one additional undeclared active pharmaceutical ingredient.
Q E Bhorat, Soweto Clinical Trials Centre, Johannesburg, South Africa
A E Bhorat, Soweto Clinical Trials Centre, Johannesburg, South Africa
Full TextPDF (104KB)
Cite this article
Date published: 2021-02-18
Full text views: 611